- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Interventions
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
- Biological · Radiation · Procedure
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
- Interventions
- rQNestin, Cyclophosphamide, Stereotactic biopsy
- Drug · Procedure
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Interventions
- AdV-tk, Valacyclovir
- Biological · Drug
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Aglatimagene besadenovec
- Biological
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Farmington, Connecticut • New Haven, Connecticut + 10 more
- Conditions
- Malignant Glioma, Recurrent Ependymoma
- Interventions
- AdV-tk, valacyclovir, Radiation
- Biological · Drug · Radiation
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Interventions
- CAN-2409, Valacyclovir, Temozolomide, Radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Columbus, Ohio + 1 more
- Conditions
- Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer
- Interventions
- AdV-tk + valacyclovir
- Biological
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Glioma, Malignant
- Interventions
- AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
- Conditions
- Prostate Cancer
- Interventions
- aglatimagene besadenovec, placebo, valacyclovir
- Biological · Drug
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 22
- States / cities
- Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
- Conditions
- Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- Interventions
- aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
- Biological · Radiation
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 7
- States / cities
- Peoria, Arizona • Lakewood, Colorado • Littleton, Colorado + 4 more
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- AdV-tk, Valacyclovir
- Biological · Drug
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Duarte, California • La Jolla, California • Columbus, Ohio
- Conditions
- Prostate Cancer
- Interventions
- Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir
- Biological
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2030
- U.S. locations
- 72
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more
- Conditions
- Lung Cancer
- Interventions
- CAN-2409 + valacyclovir
- Biological
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-squamous, Non-Small Cell Lung Cancer
- Interventions
- Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New York, New York